ImpediMed Management
Management criteria checks 0/4
ImpediMed's CEO is Parmjot Bains, appointed in Jan 2024, has a tenure of 1.83 years. total yearly compensation is A$756.34K, comprised of 60.8% salary and 39.2% bonuses, including company stock and options. directly owns 0.001% of the company’s shares, worth A$820.68. The average tenure of the management team and the board of directors is 1.8 years and 2.2 years respectively.
Key information
Parmjot Bains
Chief executive officer
AU$756.3k
Total compensation
| CEO salary percentage | 60.82% |
| CEO tenure | 1.8yrs |
| CEO ownership | 0.001% |
| Management average tenure | 1.8yrs |
| Board average tenure | 2.2yrs |
Recent management updates
Recent updates
We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth
Jun 26
ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans
Mar 05Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth
Nov 23Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?
Jul 11We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully
Mar 27Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation
Sep 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | AU$756k | AU$460k | -AU$23m |
| Mar 31 2025 | n/a | n/a | -AU$22m |
| Dec 31 2024 | n/a | n/a | -AU$21m |
| Sep 30 2024 | n/a | n/a | -AU$21m |
| Jun 30 2024 | AU$431k | AU$199k | -AU$20m |
Compensation vs Market: Parmjot's total compensation ($USD495.44K) is above average for companies of similar size in the Australian market ($USD295.28K).
Compensation vs Earnings: Parmjot's compensation has increased whilst the company is unprofitable.
CEO
Parmjot Bains
Dr. Parmjot Bains, M.D. serves as Managing Director at ImpediMed Limited from January 08, 2023 and serves as its CEO since July 22, 2024 and serves as its Director from 2024 and served as its Chief Executi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 1.8yrs | AU$756.34k | 0.0011% A$ 820.7 | |
| CFO & Executive Director | 2yrs | AU$633.67k | 0.10% A$ 78.1k | |
| Senior Vice President of R&D and Technology | no data | AU$704.20k | no data | |
| VP of Business Development & Investor Relations | less than a year | no data | no data | |
| Senior Vice President of US Sales | less than a year | no data | no data | |
| Senior Director of Marketing | 2.8yrs | no data | no data | |
| Director of Human Resources | 1.3yrs | no data | no data | |
| Chief Medical Officer | 2.2yrs | no data | no data | |
| Chief Product Officer | less than a year | no data | no data | |
| Company Secretary | 10.8yrs | no data | no data |
Experienced Management: IPD's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 1.8yrs | AU$756.34k | 0.0011% A$ 820.7 | |
| CFO & Executive Director | 2.2yrs | AU$633.67k | 0.10% A$ 78.1k | |
| Independent Non-Executive Chair | 2.2yrs | AU$198.00k | 0.18% A$ 135.5k | |
| Non-Executive Director | 2.2yrs | AU$209.70k | 0.14% A$ 109.2k | |
| Independent Non-Executive Director | 2.2yrs | AU$112.00k | 0.24% A$ 182.5k | |
| Independent Non-Executive Director | 1.4yrs | AU$112.00k | 0.092% A$ 71.2k |
Experienced Board: IPD's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/29 19:48 |
| End of Day Share Price | 2025/11/28 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ImpediMed Limited is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shane Storey | Canaccord Genuity |
| Scott Power | Morgans Financial Limited |
| Thomas Godfrey | Ord Minnett Limited |